These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 936985)

  • 21. Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
    Bos R; Nieuwenhuizen W
    Ann N Y Acad Sci; 1992 Dec; 667():428-30. PubMed ID: 1309066
    [No Abstract]   [Full Text] [Related]  

  • 22. Urokinase immobilized on medical polymeric materials: fundamental and clinical studies.
    Ohshiro T; Kosaki G
    Artif Organs; 1980 Feb; 4(1):58-4. PubMed ID: 6989347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
    Cassels R; Fears R; Smith RA
    Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in the activation rates of plasminogen by tissue plasminogen activator and urokinase.
    Takada A; Shizume K; Cho M; Takada Y
    Thromb Res; 1987 Feb; 45(4):371-81. PubMed ID: 2437668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrinogen-fibrin related antigen pattern in human blood. Incomplete lysis of whole blood clots by urokinase.
    Jacobsen CD; Fry GL; Wu KK; Southers NJ
    Thromb Res; 1975 Apr; 6(4):327-36. PubMed ID: 1079637
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative study of different urokinase preparations.
    Millar WT; Smith JF
    Thromb Res; 1983 Jun; 30(5):425-9. PubMed ID: 6351343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vitro measurement of fibrinolysis by urokinase].
    Senf L
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):819-21. PubMed ID: 6176506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained fibrinolytic activity in the euglobulin fraction induced by concomitant administration of urokinase and dextran sulphate.
    Matsuo O; Kawaguchi T; Kosugi T; Mihara H
    Thromb Res; 1978 Dec; 13(6):1125-30. PubMed ID: 749265
    [No Abstract]   [Full Text] [Related]  

  • 29. Activation of Glu-plasminogen by urokinase in the presence of fibrinogen, fibrin, and SK-potentiator.
    Takada A; Takada Y
    Thromb Res; 1981 May; 22(4):497-501. PubMed ID: 6457416
    [No Abstract]   [Full Text] [Related]  

  • 30. [In vitro study of a human plasmin (CY 218) and its association with urokinase (author's transl)].
    Brochier M; Griguer P
    Rev Med Brux; 1981 Mar; 2(3):167-74. PubMed ID: 6453415
    [No Abstract]   [Full Text] [Related]  

  • 31. The plasminogen activator and esterase activities of the two forms of urokinase.
    Ong EB; Soberano ME; Johnson AJ; Dharmgrongartama ED
    Thromb Res; 1981 Nov; 24(3):223-32. PubMed ID: 7038974
    [No Abstract]   [Full Text] [Related]  

  • 32. Leukocyte-plasma interaction in fibrinolysis. A new dimension in the action of urokinase.
    Moroz LA; Sniderman AD; Marpole DG
    N Engl J Med; 1979 Nov; 301(20):1100-4. PubMed ID: 158709
    [No Abstract]   [Full Text] [Related]  

  • 33. Enhancement of vitreous clot lysis by urokinase: mode of action.
    Forrester JV; Edgar W; Millar W; Prentice CR; Williamson J
    Exp Eye Res; 1982 Jun; 34(6):895-907. PubMed ID: 6211365
    [No Abstract]   [Full Text] [Related]  

  • 34. Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism.
    Marder VJ; Donahoe JF; Bell WR; Cranley JJ; Kwaan HC; Sashara AA; Barlow GH
    J Lab Clin Med; 1978 Nov; 92(5):721-9. PubMed ID: 712206
    [No Abstract]   [Full Text] [Related]  

  • 35. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V; Pannell R
    Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrinolysis of soluble and polymerized des-AA/des-AABB fibrin compared to fibrinogenolysis in buffer and in fibrinogen-boosted serum. Evidence that plasminogen activators are responsible for preferential degradation of polymerized fibrin.
    Brosstad F
    Thromb Res; 1979; 15(3-4):497-504. PubMed ID: 158847
    [No Abstract]   [Full Text] [Related]  

  • 37. Salivary fibrinolytic activity before and after oral surgery estimated on different types of fibrin.
    Gersel-Pedersin N
    Int J Oral Surg; 1976 Dec; 5(6):270-5. PubMed ID: 826490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Studies on coagulation and fibrinolysis. III. Urokinase activated fibrinolysodynamicogram].
    Hu YM; Xue H; Wang KQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1982 Jun; 4(3):133-6. PubMed ID: 6215134
    [No Abstract]   [Full Text] [Related]  

  • 39. [Low molecular weight heparin and high and low molecular weight urokinase in fibrinolysis in vivo].
    Badimón L; Villaverde CA; Vidal M; Valdecasas FG
    Arch Farmacol Toxicol; 1979 Dec; 5(3):262-4. PubMed ID: 397803
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
    Lee KN; Jackson KW; McKee PA
    Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.